Source: ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Catherina L. Chang, Conroy Wong, Lutz Beckert, Eskandarain Shafuddin, Richard Beasley, Robert Young, Robert J. Hancox. ß-blockers in exacerbations of COPD: feasibility of a randomised controlled trial. ERJ Open Res, 3 (1) 00090-2016; 10.1183/23120541.00090-2016

Member's Comments

No comment yet.

Related content which might interest you: Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study Source: Eur Respir J, 58 (1) 2001798; 10.1183/13993003.01798-2020 Year: 2021 Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials Source: ERJ Open Res, 5 (2) 00072-2019; 10.1183/23120541.00072-2019 Year: 2019 A self-management programme for COPD: a randomised controlled trial Source: Eur Respir J 2014; 44: 1538-1547 Year: 2014 A randomised controlled trial of zafirlukast in acute asthma Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005 Acute effects of nasal high-flow during exercise in COPD patients after an exacerbation : a randomized controlled cross-over trial Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care Year: 2017 Home nasal high-flow following severe COPD exacerbation: a mixed-methods feasibility randomised controlled trial Source: Virtual Congress 2021 – New trends in non-invasive respiratory support Year: 2021 Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial Source: Eur Respir J, 54 (5) 1802134; 10.1183/13993003.02134-2018 Year: 2019 Targeting dynamic hyperinflation in moderate-to-severe asthma: a randomised controlled trial Source: ERJ Open Res, 7 (3) 00738-2020; 10.1183/23120541.00738-2020 Year: 2021 Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006 Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial Source: International Congress 2019 – Airway infection in COPD Year: 2019 Effectiveness of a pharmacist-led inhalation technique intervention on asthma and COPD patients: The INspira cluster-randomized controlled trial Source: Virtual Congress 2021 – Highlights for primary care in 2021 Year: 2021 Early pulmonary rehabilitation after acute exacerbation of COPD: a randomised controlled trial Source: ERJ Open Res, 6 (1) 00173-2019; 10.1183/23120541.00173-2019 Year: 2020 Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? Source: ERJ Open Res 2016: 00055-2016 Year: 2016 RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021 Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017 Year: 2018 A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care Year: 2012